TGFβ1 SNPs and radio-induced toxicity in prostate cancer patients

• Published in: Radiotherapy and oncology Vol. 103; no. 2; pp. 206 - 209
• Main Authors: Fachal, Laura, Gómez-Caamaño, Antonio, Sánchez-García, Manuel, Carballo, Ana, Peleteiro, Paula, Lobato-Busto, Ramón, Carracedo, Ángel, Vega, Ana
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 01.05.2012
• Subjects: Case-Control Studies; Haplotypes; Hematology, Oncology and Palliative Medicine; Humans; Male; Polymorphism; Polymorphism, Single Nucleotide; Prostate cancer; Prostatic Neoplasms - radiotherapy; Radiotherapy; Radiotherapy, Conformal - adverse effects; SNP; TGFβ1; Toxicity; Transforming Growth Factor beta1 - genetics; TGFβ1; SNP; Radiotherapy; Toxicity; Prostate cancer; Polymorphism
• ISSN: 0167-8140; 1879-0887
• DOI: 10.1016/j.radonc.2012.01.015

Abstract Background and purpose We have performed a case-control study in 413 prostate cancer patients to test for association between TGFβ1 and the development of late normal-tissue toxicity among prostate cancer patients treated with three-dimensional conformational radiotherapy (3D-CRT) Materials and methods Late gastrointestinal and genitourinary toxicities were assessed for at least two years after radiotherapy in 413 patients according to CTCAEvs3 scores. Codominant genotypic tests and haplotypic analyses were undertaken to evaluate the correlation between TGFβ1 SNPs rs1800469, rs1800470 and rs1800472 and radio-induced toxicity. Results Neither the SNPs nor the haplotypes were found to be associated with the risk of late toxicity. Conclusions We were able to exclude up to a 2-fold increase in the risk of developing late gastrointestinal and genitourinary radio-induced toxicity due to the TGFβ1 SNPs rs1800469 and rs1800470, as well as the two most frequent TGFβ1 haplotypes.